Smith & Nephew Plc SNN 深 沪
已收盘 09-26 16:00:00 美东时间
35.42
+0.140
+0.40%
华盛通- 最 高35.62
- 今 开35.56
- 成交量 49.71万股
- 最 低 35.35
- 昨 收 35.28
- 总市值 155.14亿
- 52周最高 38.79
- 市盈率 静 37.64
- 换手率 0.11%
- 52周最低 23.243
- 委 比 78.57%
- 总股本 4.38亿
- 历史最高 48.168
- 量 比 0.67
- 振 幅 0.77%
- 历史最低 8.968
- 每 手 1
- 风险率 4.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trump Administration Review Targets Medical Supply Chain Vulnerabilities
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
09-26 02:07
Sun Country Airlines Appoints Wendy Schoppert to Board of Directors
Sun Country Airlines has appointed Wendy Schoppert to its Board of Directors, effective October 1, 2025. Schoppert brings extensive experience as a corporate board director across retail, financial services, and health care industries. She currently chairs The ODP Corporation/Office Depot and serves on the boards of Davita, Inc. and Fossil Inc. Her executive career includes senior roles at Sleep Number Corporation and earlier positions at U.S. Ba...
09-22 17:01
重磅！不用英伟达GPU ！中科院类脑脉冲大模型“瞬悉1.0”用国产GPU实现训练效率提升百倍！
（来源：电子创新网） 据中国科学院官网信息，近日，中国科学院自动化研究所李国齐和徐波团队与相关单位合作，推出类脑脉冲大模型“瞬悉1.0”（SpikingBra...
09-18 09:20
Smith & Nephew Announces Share Sale by Executive
Smith & Nephew Snats ( ($SNN) ) has provided an update. On September 9, 202...
09-10 01:58
What Does the Market Think About Smith & Nephew?
Smith & Nephew's (NYSE:SNN) short percent of float has risen 6.56% since it...
09-04 04:00
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
<p>Smith+Nephew has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma to promote wound healing. The system is designed for chronic exuding wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It is CMS-covered for diabetic patients with chronic wounds under certain conditions. The system can be tailored for wound shape and depth with a single bl...
09-03 14:16
Smith & Nephew Grants Share Awards to Executive
Smith & Nephew Snats ( ($SNN) ) has provided an announcement. On August 27,...
08-30 00:47
Smith+Nephew Appoints Dr. Garheng Kong as Non-Executive Director
Smith & Nephew Snats ( ($SNN) ) has shared an announcement. On August 28, 2...
08-28 18:57
Smith & Nephew Aligns Director Compensation with Shareholder Interests
An update from Smith & Nephew Snats ( ($SNN) ) is now available. On August ...
08-27 00:57
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
Sionna Therapeutics initiated a Phase 1 trial evaluating SION-451, a first-in-class NBD1 stabilizer, in combination with SION-2222 and SION-109 for cystic fibrosis treatment. The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers, with topline data expected mid-2026. Sionna seeks to revolutionize CF treatment by targeting CFTR dysfunction via NBD1 stabilization, addressing an unmet need for therapies that direct...
08-25 11:00
